Celldex Therapeutics, Inc. (CLDX)

Oncology Corporate Profile

Stock Performance


HQ Location

222 Cameron Drive, Suite 400
Phillipsburg, NJ 8865

Company Description

Celldex Therapeutics is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.

Website: http://www.celldextherapeutics.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
rindopepimut / CDX-110immunotherapy (targeting EGFRvIII)1st line metastatic Breast cancerII
CDK-011antibody drug conjugate1st line metastatic MelanomaIIAmgen
rindopepimut / CDX-110immunotherapy (targeting EGFRvIII)1st line metastatic MelanomaII
glembatumumab vedotin / CDX-011antibody drug conjugate (ADC)2nd line metastatic Breast cancerII
CDX-011antibody drug conjugateBreast cancerIIAmgen
glembatumumab vedotin / CDX-011antibody drug conjugate (ADC)MelanomaII
CDX-301Fms-like tyrosine kinase 3 ligandVarious cancer typesII
CDX-301Fms-like tyrosine kinase 3 ligandDiffuse large B-cell Lymphoma (DLBCL)I
varlilumab (+ Ipilimumab) / CDX-1127monoclonal antibodyMelanomaIBristol-Myers Squibb
varlilumab (+ atezolizumab) / CDX-1127monoclonal antibodyRenal cell carcinoma (RCC)IRoche
CDX-1401immunotherapyVarious cancer typesI
varlilumab / CDX-1127monoclonal antibodyVarious cancer typesI
varlilumab (+ Opdivo®) / CDX-1127monoclonal antibodyVarious cancer typesI
CDX-011antibody drug conjugateBrain cancerPreclinicalAmgen
CDX-011antibody drug conjugateOvarian cancerPreclinicalAmgen
CDX-011antibody drug conjugateRenal cell carcinoma (RCC)PreclinicalAmgen

View additional information on product candidates here »

Source: http://www.celldextherapeutics.com

Recent News Headlines

Celldex, Aiming For More Cancer Drug Combos, Pays $62.5M For Kolltan

11/2/2016 04:34 pm

(Xconomy New York) Nov 1, 2016 - Celldex Therapeutics has been trying to bounce back ever since its lead drug, a cancer vaccine, fell short in clinical trials earlier this year.

Incyte Announces First Patient Treated in ECHO-301 Phase 3 Study

6/23/2016 10:05 am

(Yahoo! Finance) June 23, 2016 - Pivotal trial to evaluate epacadostat in combination with Keytruda® (pembrolizumab) as first-line treatment for patients with advanced or metastatic melanoma.

Celldex Therapeutics’ CDX-1401, CDX-301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma

6/4/2016 10:15 pm

(NASDAQ) June 4, 2016 - Celldex Therapeutics, Inc. announced today results from a Phase 2 clinical study evaluating CDX-1401 and CDX-301 in patients with malignant melanoma.

Celldex Therapeutics Initiates Phase 1/2 Study of Glembatumumab Vedotin in Squamous Cell Lung Cancer

4/27/2016 05:00 pm

(Yahoo! Finance) Apr 27, 2016 - Celldex Therapeutics, Inc. today announced that it has initiated an open-label Phase 1/2 safety and tolerability study of glembatumumab vedotin in patients with unresectable stage IIIB or IV, gpNMB-expressing, advanced or metastatic squamous cell carcinoma (SCC) of the lung, who have progressed on prior platinum-based chemotherapy.

Celldex Therapeutics Presents Data Supporting the Clinical Development of Glembatumumab Vedotin and the Preclinical CD40 Program at the AACR Annual Meeting 2016

4/20/2016 05:10 pm

(Yahoo! Finance) Apr 20, 2016 - Celldex Therapeutics, Inc. announced three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans.

Celldex Therapeutics Presents Favorable Safety Profile and Immune Response Data from Phase 1/2 Study of Varlilumab and Nivolumab at the AACR Annual Meeting 2016

4/18/2016 04:19 pm

(Celldex) Apr 18, 2016 - Celldex Therapeutics, Inc. announced today new safety and immune response data from the Phase 1 portion of a Phase 1/2 dose escalation and cohort expansion study examining the investigational combination of varlilumab, Celldex's CD27 targeting investigational immune-activating antibody, and Bristol-Myers Squibb's anti-PD-1 immunotherapy Opdivo® (nivolumab).

Celldex’s Brain Cancer Vaccine Fails Key Phase 3 Test, Shares Fall

3/7/2016 05:43 pm

(Xconomy Boston) Mar 7, 2016 - Rindopepimut has failed in a critical late-stage study, leaving its future very much in doubt.

Data Safety and Monitoring Board Recommends Celldex’s Phase 3 Study of RINTEGA® (rindopepimut) in Newly Diagnosed Glioblastoma be Discontinued as it is Unlikely to Meet Primary Overall Survival Endpoint in Patients with Minimal Residual Disease

3/7/2016 01:01 pm

(Celldex Therapeutics) Mar 7, 2016 - Celldex Therapeutics, Inc. today announced that the independent Data Safety and Monitoring Board (DSMB) has determined, based on a preplanned interim analysis, that continuation of the Phase 3 ACT IV study of RINTEGA® (rindopepimut) in patients with newly diagnosed EGFRvIII-positive glioblastoma will not reach statistical significance for overall survival in patients with minimal residual disease, the primary endpoint of the study, as both the RINTEGA arm and the control arm are performing on par with each other.

New Research Shows How Financial Engineering Could Make Life-Saving Drugs More Available And Affordable

2/25/2016 12:00 pm

(Dana-Farber) Feb 24, 2016 - Stratospheric costs for therapies not yet covered by insurance put some drugs out of reach for many patients. Securitized consumer healthcare loans could spread the cost of therapies over many years providing more patients access to the drugs.

CURE Media Group Launches Multiple Myeloma Heroes Awards Event to Honor Individuals Making Difference in Multiple Myeloma

2/9/2016 11:05 am

(PRWeb) Feb 8, 2016 - CURE Media Group, the nation’s leading digital and print media enterprise focused on cancer patients, has officially launched the Multiple Myeloma Heroes Awards event, which will annually honor individuals making heroic contributions in the field of multiple myeloma (MM) or in the lives of patients with MM.

Celldex Nears Pivotal Decision Point for Brain Tumor Therapy

1/29/2016 04:32 pm

(TheStreet) Jan 28, 2016 - Celldex will announce the outcome of an interim analysis for a pivotal study of its brain tumor therapy Rintega within weeks.

Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Atezolizumab in Renal Cell Carcinoma

12/8/2015 05:30 pm

(StreetInsider) Dec 8, 2015 - Celldex Therapeutics, Inc. today announced the initiation of an open-label, Phase 1/2 safety and tolerability study examining the investigational combination of varlilumab and Roche's atezolizumab (MPDL3280A) in patients with unresectable stage III or IV renal cell carcinoma (RCC).

Brain Cancer Vaccine Gets Better With Time, as Celldex Shows Survival Edge

11/23/2015 05:22 pm

(Forbes) Nov 20, 2015 - The company’s experimental immune-booster for certain types of brain cancer showed, in a small study of 73 patients, it could reduce the risk of death by 47 percent when compared with a placebo.

Celldex Therapy Extends Life for Those With Brain Cancer

11/23/2015 12:52 pm

(Bloomberg) Nov 20, 2015 - Celldex Therapeutics Inc.’s cancer vaccine lengthened some patients’ lives in a midstage trial, potentially giving hope for treatment of a brain cancer that has no effective options for patients.

Biotech Stock Mailbag: Celldex, Bluebird, Kite, Inovio

8/21/2015 05:19 pm

(TheStreet) Aug 21, 2015 - Biotech columnist Adam Feuerstein answers readers' questions about health care.

Jimmy Carter to Discuss Cancer Diagnoses Thursday

8/19/2015 11:05 am

(CNN) Aug 18, 2015 - Former President Jimmy Carter has scheduled a Thursday morning news conference to discuss his cancer diagnosis.

AstraZeneca Announces New Gene Therapy Collaboration

8/3/2015 12:04 pm

(PharmaTimes [UK]) Aug 3, 2015 - AstraZeneca and Isis Pharmaceuticals will collaborate to develop antisense therapies for cardiovascular, metabolic and renal diseases.

Op-Ed: Should We Charge Patients for Medical Research?

8/3/2015 12:01 pm

(New York Times) July 31, 2015 - A few months ago, we got a call from a former oncology professor of ours.

ZAI Lab Announces A Global Licensing Agreement With Sanofi For A Novel Compound To Potentially Treat NSCLC

8/3/2015 12:01 pm

(ZAI Lab) July 31, 2015 - ZAI Lab Limited, an innovative biotech company based in China, announced today that it has entered into a global licensing agreement with Sanofi for a novel multi-kinase inhibitor for the potential treatment of non-small cell lung cancer and other oncology indications.

Amgen to Undergo Experimental Treatment

8/3/2015 12:00 pm

(Wall Street Journal) July 31, 2015 - The U.S. is about to experiment with biosimilars. Amgen, which reported solid second-quarter results Thursday, will play the role of guinea pig.

Opinion: Will Trans-Pacific Partnership Hold Back New Generic Drugs?

8/3/2015 11:05 am

(Los Angeles Times/Opinion L.A.) Aug 1, 2015 - The Times' editorial board, which has long supported free-trade deals, sounded a note of caution Friday about the next one in the pipeline, the Trans-Pacific Partnership.

AMA Wants Doctor Input on EHRs, Meaningful Use

8/3/2015 11:04 am

(Monthly Prescribing Reference/HealthDay News) July 31, 2015 - The American Medical Association is encouraging clinicians to share their perspectives on electronic heath records and the meaningful use program.

Bavarian Nordic Targeted by Short Seller’s Drug Critique

8/3/2015 11:03 am

(Bloomberg) Aug 3, 2015 - An investor that would benefit from a drop in Bavarian Nordic A/S shares issued a report saying that the Danish biotechnology company’s experimental prostate cancer vaccine will probably fail in late-stage testing.

BeiGene Receives Approval to Initiate Clinical Trials in China With BGB-283 for Solid Tumor Cancers

8/3/2015 11:02 am

(StreetInsider) Aug 3, 2015 - CTA approval received in China by BeiGene for a novel RAF dimer inhibitor that targets both B-RAF and K-RAS/N-RAS mutated cancers.

Swiss Drug Maker Roche Being Probed In Romania In Wide-Ranging Medical Corruption Case

8/3/2015 11:01 am

(Fox Business/Associated Press) July 31, 2015 - Swiss pharmaceuticals company Roche confirms it is being investigated by anti-corruption prosecutors looking for evidence that drug companies offered doctors vacations and other incentives in exchange for prescribing cancer drugs.

Samsung Electronics to Create Fund For Cancer-Stricken Workers, Safety

8/3/2015 11:01 am

(Reuters) Aug 3, 2015 - Tech giant Samsung Electronics Co Ltd said on Monday it will create a 100 billion won ($85.8 million) fund to compensate cancer-stricken workers and their families, and for efforts to prevent such diseases at its chip and display factories.

NCCN Seeking Poster Presentations From Nation's Top Oncology Researchers

8/3/2015 11:01 am

(NCCN) Aug 3, 2015 - NCCN is now accepting original abstracts from investigators for consideration for the NCCN 21st Annual Conference General Poster Session; the deadline for submissions is Friday, November 6, 2015.

Nominations Open for 2016 Pezcoller Foundation-AACR International Award for Cancer Research

8/3/2015 11:01 am

(AACR) July 31, 2015 - The American Association for Cancer Research (AACR) is accepting nominations for the 2016 Pezcoller Foundation-AACR International Award for Cancer Research.

Action Alert: Mesothelioma Bill in Congress for Patient Registry

8/3/2015 11:01 am

(The Meso Foundation/Cure Meso blog) July 29, 2015 - This bipartisan bill would establish the nation’s first formal federal registry to track mesothelioma patients.

Mattie Miracle Cancer Foundation Announces Completion Of Psychosocial Standards Of Care For Children With Cancer

8/3/2015 11:01 am

(Mattie Miracle Cancer Foundation) July 31, 2015 - Today, at the World Congress of Psycho-Oncology, leading researchers and clinicians dedicated to the psychosocial needs of children with cancer announced the completion of the Psychosocial Standards of Care to be published in a 2015 special issue of Pediatric Blood and Cancer.

Commentary: Practice-Changing Results From ASCO 2015: Immunotherapy in Previously Treated Advanced Non-Small Cell Lung Cancer

8/3/2015 11:00 am

(Medscape Medical News) July 31, 2015 - Dr. Jack West provides an analysis of practice-changing studies presented at ASCO 2015, with a focus on lung cancer.

Why Breast-Cancer Survivors Gain More Weight

7/15/2015 11:02 am

(TIME) July 15, 2015 - Tumors and treatment may make it easier to put on pounds, and the latest research shows why breast cancer patients should be aware of the dangers of gaining too much.

How the CMS Plans for ICD-10 Implementation Will Affect Hematologists

7/8/2015 11:05 am

(ASH) July 7, 2015 - The Centers for Medicare and Medicaid Services (CMS) has announced a new plan that will introduce some leniency in the introduction of the new ICD-10 diagnosis coding system.

The US Oncology Network Applauds Introduction of Medicare Patient Access to Treatment Act

6/30/2015 12:01 pm

(The US Oncology Network) June 25, 2015 – The US Oncology Network – one of the nation's largest networks of integrated, community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care – today commended Representatives Mike Pompeo (R-KS) and Don Beyer (D-VA) for introducing the Medicare Patient Access to Treatment Act, legislation to level the playing field by creating a more adequate reimbursement structure for cancer care delivered in the community setting.

Independent Data Safety and Monitoring Board Recommends Continuation of Celldex's Phase 3 Study of RINTEGA(R) (rindopepimut) in Newly Diagnosed Glioblastoma

6/29/2015 04:11 pm

(CNN Money) June 29, 2015 - Celldex Therapeutics, Inc. today announced that an independent Data Safety and Monitoring Board (DSMB) recommended continuation of the Phase 3 ACT IV study of RINTEGA® (rindopepimut) in patients with newly diagnosed glioblastoma.

Celldex Builds Case for Brain Cancer Vaccine With New ASCO Data

6/1/2015 12:11 am

(Xconomy New York) May 31, 2015 - Celldex Therapeutics grabbed the spotlight late last year when an experimental vaccine it’s been developing helped extend the lives of some patients with an aggressive, deadly form of brain cancer.

ASCO '15: Celldex Immunotherapy Maintains Survival Benefit for Recurrent Brain Tumor Patients

5/31/2015 11:41 pm

(TheStreet) May 31, 2015 - An experimental, targeted immunotherapy developed by Celldex Therapeutics continues to delay tumor growth and extend survival in patients with a certain type of recurrent brain tumor, according to an update of a clinical trial disclosed Sunday.

All Eyes on Celldex as It Readies to Release Brain-Cancer Trial Results

5/29/2015 08:05 pm

(Boston Business Journal/Bioflash blog) May 29, 2015 - It’s been called the deadliest form of cancer, and this weekend could confirm whether a local drug developer has a treatment that could help patients with a recurrent version of it live longer.

Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Sunitinib in Metastatic Clear Cell Renal Cell Carcinoma

5/28/2015 05:27 pm

(CNNMoney) May 28, 2015 - Celldex Therapeutics, Inc. today announced the initiation of an open-label, Phase 1/2 safety and tolerability study examining the investigational combination of varlilumab and sunitinib (SUTENT®) in patients with metastatic clear cell renal cell carcinoma (CC-RCC).

Mass. General’s Cancer Center Honors Dr. William Hait

5/26/2015 12:03 pm

(MyCentralJersey) May 24, 2015 - Dr. William N. Hait of Raritan, founder of Cancer Institute of New Jersey will be honored by Massachusetts General Hospital Cancer Center May 26.

Smoking May Make Return of Lung Cancer More Likely

5/20/2015 11:03 am

(Doctors Lounge/HealthDay News) May 19, 2015 - Lung cancer survivors are at high risk for recurrence of the disease, and smoking is a major factor in that risk, a new study shows.

Celldex Therapeutics to Present Data from the ReACT Study at 2015 ASCO Annual Meeting

5/14/2015 06:19 pm

(StreetInsider) May 13, 2015 - Celldex Therapeutics, Inc. announced today that several clinical programs, including the Phase 2 ReACT study of RINTEGA® (rindopepimut) in patients with recurrent glioblastoma (GBM), will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

ELCC 2015 News: VEGF SNPs Identified as Prognostic Markers for Bevacizumab Response in Patients with Advanced Non-Squamous NSCLC

4/16/2015 12:00 am

(ESMO) Apr 16, 2015 - Patients with advanced non-squamous non-small-cell lung cancer (NS-NSCLC) achieved median overall survival (OS) longer than one year in ANGIOMET, a prospective clinical trial of bevacizumab plus carboplatin and paclitaxel, leading the investigators to look for and identify biomarkers for this response.